Novartis AG (NOVN) Given a CHF 78 Price Target at UBS AG

UBS AG set a CHF 78 price objective on Novartis AG (VTX:NOVN) in a report published on Monday. The brokerage currently has a neutral rating on the stock.

Several other research firms have also issued reports on NOVN. Morgan Stanley set a CHF 88 target price on shares of Novartis AG and gave the company a buy rating in a report on Wednesday, July 26th. Jefferies Group LLC set a CHF 97 target price on shares of Novartis AG and gave the company a buy rating in a report on Monday, July 24th. Goldman Sachs Group, Inc. (The) set a CHF 80 target price on shares of Novartis AG and gave the company a neutral rating in a report on Thursday, July 20th. Societe Generale set a CHF 91 target price on shares of Novartis AG and gave the company a buy rating in a report on Wednesday, July 19th. Finally, Deutsche Bank AG set a CHF 81 target price on shares of Novartis AG and gave the company a neutral rating in a report on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of CHF 85.37.

Novartis AG (VTX NOVN) opened at 83.25 on Monday. Novartis AG has a 1-year low of CHK 67.40 and a 1-year high of CHK 85.05. The firm has a market capitalization of CHK 195.05 billion and a P/E ratio of 30.39. The company’s 50-day moving average price is CHK 83.04 and its 200-day moving average price is CHK 80.14.

TRADEMARK VIOLATION WARNING: “Novartis AG (NOVN) Given a CHF 78 Price Target at UBS AG” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/10/24/novartis-ag-novn-given-a-chf-78-price-target-at-ubs-ag.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply